Advent Access today announced receipt of the CE Mark certificate for its award-winning av-Guardian™ vascular access system. The certificate indicates av-Guardian™’s conformity with health, safety, and environmental protection standards set by the European Union for a d...
Advent Access, an end-stage renal disease management medical technology company who designed and developed the av-Guardian™ Vascular Access System, is proud to share it has received ISO 13485:2016 certification for its Quality Management System from DEKRA Certification...
CEO Ruey Feng PEH spoke with CNBC about our invention, av-GuardianTM, and its potential to transform kidney dialysis care by allowing more patients to be treated while reducing costs. We believe that av-Guardian has the potential to assist patients in self-needling, an...
Advent Access, together with our Founder, Ruey Feng Peh, have been selected to join Silicon Valley’s prestigious Stanford StartX Community. Advent is the first medical device startup in Singapore to be selected to join the community of the best Stanford and Silicon Val...
Kidney failure patients undergoing hemodialysis suffer numerous needle insertions every week, with each prick running the risk of pain, ineffectiveness and wearing out the target vein.
Medical device startup Advent Access is going after that literal pain-point, with the...
The full results of Advent Access's First-In-Human Clinical Trial of the av-Guardian device was released at the American Society of Nephrology (ASN) Kidney Week 2018. The ASN is lauded as the most premier nephrology meeting, involving 13,000 nephrologists and the world...
Advent Access is pleased to announce that we have acquired the global manufacturing and commercialization rights to the Vwing™ Vascular Needle Guide product line and other key assets from US company, Vital Access. Our intellectual property portfolio is now one of the m...
Advent Access is pleased to announce that our av-Guardian implant technology has completed regulatory submission and key audits for the CE Mark. The clinical trial results used in this submission had also been accepted to be presented at a renowned scientific conferenc...
Did you know healthcare systems globally are spending $85 billion annually to sustain dialysis patients? Our founder, Peh Ruey Feng, shares how our lead product av-Guardian can empower patients to perform hemodialysis independently, safely, and more affordably.
Advent Access' fundraise is the largest pre-Series A financing round by a medtech startup in Southeast Asia. New funds will be used to submit CE-mark filing of av-Guardian™ in preparation for global commercialisation and to complete ongoing international clinical trial...
